Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Beat The Street With SI Traders -- Ignore unavailable to you. Want to Upgrade?

To: heinz44 who wrote (114031)	6/5/2013 3:17:06 PM
From: El Canadiense	Read Replies (2) \| Respond to of 233891

maybe your doc can double check with Abbot... "Hurry, German patient needs to uplift his thing!!"

To: heinz44 who wrote (114031)	6/6/2013 8:03:07 PM
From: El Canadiense	Read Replies (2) \| Respond to of 233891

APRI , this from me on another's APRI board... This was recently published on one of Spain's largest circulation newspapers: iqs.edu It's an interview with Peter Dunn, one of the guys involved in the discovery of Viagra.From Wikipedia: The British press portrayed Peter Dunn and Albert Wood as the inventors of the drug, a claim that Pfizer disputes.[50] Their names are on the manufacturing patent application, but the original patent on the synthesis of the drug was filed by Nicholas Terrett and Peter Ellis. Now, the first 3 questions by the journalist all revolve around "female viagra" : Will we ever get a female viagra? I tried to find something in the 90s. And? nothing worked, there's nothing working so far(!). Why? I dont know what to answer, women are more complicated at all levels (lol)... Now..now...now...I wouldnt expect this pal ( being described on the piece as currently working for an undisclosed big pharma name) to just pump a competitor's candidate, either that or he is just clueless on Femprox... which just would go to show how obscure APRI is yet. Since he is currently doing some work for a Chemical Institute in my hometown Barcelona and doing public presentations from time to me (he just did one in May before the interview), I will try to track him down and discuss Femprox with him and report back to this board.Should make for an interesting conversation... On the other side of the equation, just think of the journalist and what sort of headline he was trying to get first thing....what sort of public attraction could a succesfull Femprox bring to APRI? Just thought I would share this as food for thought with you guys....